ProCE Banner Activity

MANIFEST: Novel BET Inhibitor, CPI-0610, Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Patients

Slideset Download
Conference Coverage
Combination therapy with CPI-0610, a novel BET inhibitor, plus ruxolitinib shows promising activity in JAK inhibitor–naive patients with myelofibrosis in this phase II study.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology